<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90557">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01701453</url>
  </required_header>
  <id_info>
    <org_study_id>2011-12-070</org_study_id>
    <nct_id>NCT01701453</nct_id>
  </id_info>
  <brief_title>Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)</brief_title>
  <official_title>Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Objective To test the safety of 6 month-duration of DAPT compared to conventional
           12-month-or-longer duration after new generation DES implantation in patients with
           acute coronary syndrome.

        2. Hypothesis A 6-month duration of DAPT is non-inferior to a conventional
           12-month-or-longer duration of DAPT at preventing the occurrence of major adverse
           cardiac and cerebrovascular events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary endpoint composite of death, spontaneous MI, stent thrombosis, cerebrovascular
           events or BARC Type 3, 4 and 5 bleeding over the 6- to 18-month for comparison of
           6-month vs. 12-month or longer clopidogrel treatment

        2. Secondary endpoint 1) 6- to 18-month each component of primary endpoint 2) 6- to
           18-month death, or myocardial infarction (MI) 3) 6- to 18-month cardiac death 4) 6- to
           18-month target vessel failure (TVF) : cardiac death, MI in the target vessel
           territory, target vessel revascularization (TVR) 5) 6- to 18-month major adverse
           cardiac and cerebrovascular events (all death, MI, cerebrovascular event,
           revascularization [MACCE]) 6) 6- to 36-month death, MI, cerebrovascular events, stent
           thrombosis or BARC Type 3, 4 and 5 bleeding 7) 6- to 60-month death, MI,
           cerebrovascular events, stent thrombosis or BARC Type 3, 4 and 5 bleeding
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite of death, spontaneous myocardial infarction [MI], cerebrovascular event, stent thrombosis, or BARC Type 3, 4 and 5 bleeding</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any cause of death</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any cause of death or spontaneous MI</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure defined as cardiac death, MI in the target vessel territory, target vessel revascularization (TVR)</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events [MACCE] defined as all death, MI, cerebrovascular event, any revascularization</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any cause of death, MI, cerebrovascular events, stent thrombosis or BARC Type 3, 4 and 5 bleeding</measure>
    <time_frame>over the 6- to 36-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any cause of death, MI, cerebrovascular events, stent thrombosis or BARC Type 3, 4 and 5 bleeding</measure>
    <time_frame>over the 6- to 60-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular event</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC Type 3, 4 and 5 bleeding</measure>
    <time_frame>over the 6- to 18-month postindex hospitalization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>6 months group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6months duration clopidogrel treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 months  or longer  group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 months  or longer duration  clopidogrel treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <arm_group_label>6 months group</arm_group_label>
    <arm_group_label>12 months  or longer  group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 20 years of age.

          2. Subject must have evidence of acute coronary syndrome (e.g., unstable angina, NSTEMI,
             or STEMI)

          3. Subject is able to verbally confirm understandings of risks, benefits and treatment
             alternatives of receiving 6-month or 12-month or longer duration of DAPT and he/she
             or his/her legally authorized representative provides written informed consent prior
             to any study related procedure.

        Exclusion Criteria:

          1. An elective surgical procedure is planned that would necessitate interruption of
             thienopyridines during the first 12 months post enrollment.

          2. Patients with cardiogenic shock

          3. Subjects who have dialysis.

          4. Women who are pregnant or breast feeing

          5. Less than 2years life expectancy by previous medical history

          6. Patients with hypersensitivity or contraindications for aspirin or clopidogrel

          7. Patients who need long-tem clopidogrel taking due to cerebral infarction or other
             diseases

          8. Patients who can not give written consent such as mental illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyeon-Cheol Gwon, PhD</last_name>
    <phone>82-2-3410-3418</phone>
    <email>hcgwon@skku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Bin Song, MD</last_name>
    <phone>82-2-3410-3419</phone>
    <email>youngbin.song@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoen-Cheol Gwon, PhD</last_name>
      <phone>82-2-3410-3418</phone>
      <email>hcgwon@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Hyoen-Cheol Gwon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
      <phone>82-2-3410-3418</phone>
      <email>hc.gwon@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 7, 2013</lastchanged_date>
  <firstreceived_date>September 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeon-Cheol Gwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>duration of DAPT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
